{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T11:52:37Z","timestamp":1768477957142,"version":"3.49.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1097\/ftd.0000000000000014","type":"journal-article","created":{"date-parts":[[2013,12,16]],"date-time":"2013-12-16T10:02:24Z","timestamp":1387188144000},"page":"378-386","source":"Crossref","is-referenced-by-count":22,"title":["Population Pharmacokinetic\/Pharmacodynamic Model of Clozapine for Characterizing the Relationship Between Accumulated Exposure and PANSS Scores in Patients With Schizophrenia"],"prefix":"10.1097","volume":"36","author":[{"given":"De-Wei","family":"Shang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi-Pei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Guan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Peng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Biao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian-Yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan-Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-15-20210129","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"Kissling W, et al..","volume":"79","author":"Leucht","year":"2005","journal-title":"What does the PANSS mean Schizophr Res"},{"key":"R2-15-20210129","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00044011-200828040-00004","article-title":"Bioequivalence of clozapine orally disintegrating 100-mg tablets compared with clozapine solid oral 100-mg tablets after multiple doses in patients with schizophrenia.","volume":"28","author":"Golden","year":"2008","journal-title":"Clin Drug Investig"},{"key":"R3-15-20210129","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":". Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"issue":"suppl 3","key":"R4-15-20210129","first-page":"38","article-title":"Maximizing clozapine therapy: managing side effects.","volume":"59","author":"Lieberman","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"R5-15-20210129","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hup.2256","article-title":". Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002-2010.","volume":"27","author":"Bowskill","year":"2012","journal-title":"Hum Psychopharmacol"},{"key":"R6-15-20210129","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/hup.2223","article-title":". Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged 65 years and over: data from a therapeutic drug monitoring service, 1996-2010.","volume":"27","author":"Bowskill","year":"2012","journal-title":"Hum Psychopharmacol"},{"key":"R7-15-20210129","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/FTD.0b013e31822fbf7c","article-title":". Therapeutic drug monitoring for drugs used in the treatment of substance-related disorders: literature review using a therapeutic drug monitoring appropriateness rating scale.","volume":"33","author":"Brunen","year":"2011","journal-title":"Ther Drug Monit"},{"key":"R8-15-20210129","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/aps.2012.71","article-title":". Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia.","volume":"33","author":"Li","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"R9-15-20210129","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/FTD.0b013e31819c7037","article-title":". Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study.","volume":"31","author":"Ng","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R10-15-20210129","first-page":"59","article-title":"The study on bioequivalence of clozapine orally disintegrating tablets and tablets in Chinese healthy volunteers.","volume":"40","author":"Zheng","year":"2009","journal-title":"Guangzhou Med J"},{"key":"R11-15-20210129","first-page":"1936","article-title":". Study on bioequivalence of clozapine orally distegrating tablets in patients with schizophrenia.","volume":"31","author":"Liu","year":"2011","journal-title":"Chin J Hosp Pharm"},{"key":"R12-15-20210129","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","article-title":"Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R.","volume":"90","author":"Comets","year":"2008","journal-title":"Comput Methods Programs Biomed"},{"key":"R13-15-20210129","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","article-title":"Xposean S-PLUS based population pharmacokineticpharmacodynamic model building aid for NONMEM.","volume":"58","author":"Jonsson","year":"1998","journal-title":"Comput Methods Programs Biomed"},{"key":"R14-15-20210129","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl-speaks-NONMEM (PsN)a Perl module for NONMEM related programming.","volume":"75","author":"Lindbom","year":"1999","journal-title":"Comput Methods Programs Biomed"},{"key":"R15-15-20210129","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1046\/j.1365-2125.1997.t01-1-00606.x","article-title":". Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method.","volume":"44","author":"Jerling","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"R16-15-20210129","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/YIC.0b013e3283277627","article-title":". Determination of pharmacokinetic properties of clozapine and norclozapine in Korean schizophrenia patients.","volume":"24","author":"Lee","year":"2009","journal-title":"Int Clin Psychopharmacol"},{"key":"R17-15-20210129","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00004714-200106000-00010","article-title":". Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study.","volume":"21","author":"Gaertner","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"R18-15-20210129","first-page":"785","article-title":". Population pharmacokinetics research of clozapine in Chinese schizophrenic patients.","volume":"44","author":"Qiu","year":"2009","journal-title":"Yao Xue Xue Bao"},{"key":"R19-15-20210129","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/00003088-200746020-00003","article-title":". Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.","volume":"46","author":"Zhang","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"R20-15-20210129","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/clpt.2009.44","article-title":". Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia.","volume":"86","author":"Friberg","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"R21-15-20210129","first-page":"131","article-title":". The influence factors on pharmacokinetics of clozapine and relationship between clinical efficacy and clozapine plasma concentration in schizophrenia.","volume":"29","author":"Zhao","year":"1996","journal-title":"Chin Psychiatry"},{"key":"R22-15-20210129","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0006-3223(97)00531-3","article-title":". Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram.","volume":"44","author":"Perry","year":"1998","journal-title":"Biol Psychiatry"},{"key":"R23-15-20210129","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s002130050028","article-title":". Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics.","volume":"148","author":"Spina","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"R24-15-20210129","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/JCP.0b013e3180cac8db","article-title":". Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.","volume":"27","author":"Wu","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R25-15-20210129","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0278-5846(01)00291-3","article-title":". Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables.","volume":"26","author":"Palego","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R26-15-20210129","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/FTD.0b013e3182489a6f","article-title":". Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study.","volume":"34","author":"Uchida","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R27-15-20210129","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/JCP.0b013e3181b2fced","article-title":"Does level of care, sex, age, or choice of drug influence adherence to treatment with antipsychotics.","volume":"29","author":"Castberg","year":"2009","journal-title":"J Clin Psychopharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:27:58Z","timestamp":1620952078000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201406000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000014","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}